PMID: 9443936Jan 28, 1998Paper

Exposure of human vascular smooth muscle cells to Raf-1 antisense oligodeoxynucleotides: cellular responses and pharmacodynamic implications

Molecular Pharmacology
C SchumacherL Wennogle

Abstract

To characterize the pharmacodynamic properties of CGP 69846A/ISIS 5132, an antisense oligodeoxynucleotide directed against the mitogenic signal transducer Raf-1 kinase, we investigated the elicited biological responses in human coronary artery smooth muscle cells. Cell exposure to CGP 69846A resulted in a reversible time- and concentration-dependent down-regulation of cellular Raf-1 gene expression and, ultimately, inhibition of cell cycle progression. The highest potencies of this compound to reduce Raf-1 mRNA and protein levels were observed after 24 and 48 hr of cell exposure, respectively, with corresponding IC50 values of approximately 100 and approximately 300 nM. Proliferation was inhibited with an IC50 value of approximately 300 nM after 72 hr. We interpreted the recovery rate of Raf-1 mRNA after cell exposure to antisense ODNs as the half-life (t1/2 approximately 50 hr) of active intracellular CGP 69846A in our cell culture system. The endogenous Raf-1 turnover half-life of approximately 30 hr, as assessed by monitoring metabolically labeled Raf-1 protein, correlated kinetically with the antisense-induced protein decay rate (50% decay in approximately 33 hr), indicating that the efficiency of CGP 69846A in decreasing R...Continue Reading

References

Nov 24, 1995·Science·Z XiaM E Greenberg
Nov 10, 1995·The Journal of Biological Chemistry·A D LairdD Shalloway
Sep 1, 1995·Circulation Research·S M SchwartzE R O'Brien
Jan 1, 1995·Annual Review of Physiology·R Ross
Nov 1, 1994·Trends in Biochemical Sciences·G DaumU R Rapp
Mar 1, 1995·AJR. American Journal of Roentgenology·P M Consigny
Sep 15, 1993·Proceedings of the National Academy of Sciences of the United States of America·R MorishitaV J Dzau
May 19, 1994·The New England Journal of Medicine·G H Gibbons, V J Dzau
Apr 1, 1994·The Journal of Clinical Investigation·R MorishitaV J Dzau
Feb 1, 1994·Current Opinion in Genetics & Development·C J Marshall
Jul 9, 1993·Journal of Medicinal Chemistry·J F MilliganJ C Martin
Aug 15, 1996·Nature·M F Tuite
Dec 24, 1996·Proceedings of the National Academy of Sciences of the United States of America·B P MoniaD Fabbro

❮ Previous
Next ❯

Citations

May 31, 2002·Expert Opinion on Pharmacotherapy·Walter Kolch
Dec 22, 2016·PloS One·Xiulan Lai, Avner Friedman

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.